Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma
2022-500400-22-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial in Hodgkin lymphoma (HL) comparing Pembrolizumab arm with Brentuximab vedotin arm (2 arms). Primary endpoints: Progression-free Survival and Overall Survival. Started Nov 2022; status: completed.
02
Drugs
pembrolizumabbrentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2022-500400-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500400-22-00.